転位性腎臓細胞癌における治療戦略として,フェノタイプスクリーニングはCDK9抑制に収束する

Dharma R Thapa, Riva Deodhar, Adam Skepner

bioRxiv : the preprint server for biology

|September 5, 2025

まとめ

研究者は,転移性腎臓細胞癌 (tRCC) の新しい治療戦略を特定しました. CDK9をターゲットにすることで,TFE3融合タンパク質を抑制することで,tRCC細胞の増殖を効果的に抑制しました.

科学分野:

腫瘍学
分子生物学
薬理学について

背景:

トランスロケーション腎臓細胞癌 (tRCC) は,攻撃的な腎臓癌です.
TFE3転写因子はtRCCにとって不可欠であるが,正常な細胞には欠かせないので,治療目標としては難しい.
TFE3の基本ヘリックス・ループ・ヘリックス (bHLH) ドメインは,その機能にとって極めて重要です.

研究の目的:

クロマチン結合TFE3を調節する化合物を特定する.
tRCCの治療戦略としてCDK9抑制を調査する.
メカニズムに基づく現象性スクリーニングの有用性を実証する.

主な方法:

クロマチン結合のTFE3の調節物質を特定するために25,000の化合物のフェノタイプスクリーニング.
BRD6866を含む特定された化合物の作用機構を調査した.
エニトシクリブなどのCDK9選択性阻害剤を用いて,結果を確認した.

主要な成果:

特定されたBRD6866は, TFE3をクロマチンに閉じ込め, パン-CDK阻害剤として作用する化合物です.
BRD6866がCDK9を阻害し,TFE3の融合活動を阻害し,TFE3の標的を低下させることが示された.
CDK9阻害剤であるエニトシクリブはこれらの効果を再現し,tRCC細胞の増殖を抑制しました.

結論:

CDK9抑制は,転移性腎臓細胞癌に対する有望な治療戦略です.
TFE3のような困難な治療標的をターゲットにするために,メカニズムに基づくフェノタイプスクリーニングは有効です.
CDK9阻害によるTFE3誘発型tRCCを標的とした治療は,新しい治療法を提供します.

さらに関連する動画

12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

関連する概念動画

02:34

Inhibition of Cdk Activity

4.9K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

4.9K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

02:15

M-Cdk Drives Transition Into Mitosis

5.7K

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

5.7K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:20

The Retinoblastoma Gene

4.2K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

4.2K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...